Halyard Health, Inc. (NYSE:HYH) – Investment analysts at KeyCorp lowered their Q3 2017 earnings per share (EPS) estimates for shares of Halyard Health in a research report issued to clients and investors on Wednesday. KeyCorp analyst M. Mishan now anticipates that the medical instruments supplier will post earnings per share of $0.45 for the quarter, down from their previous estimate of $0.47. KeyCorp currently has a “Hold” rating on the stock. KeyCorp also issued estimates for Halyard Health’s Q4 2017 earnings at $0.51 EPS.

A number of other equities analysts have also weighed in on HYH. Stephens upgraded shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a research report on Thursday, August 3rd. Zacks Investment Research upgraded shares of Halyard Health from a “sell” rating to a “hold” rating in a research report on Thursday. BidaskClub upgraded shares of Halyard Health from a “hold” rating to a “buy” rating in a research report on Saturday, August 19th. Stifel Nicolaus restated a “buy” rating and set a $45.00 target price on shares of Halyard Health in a research report on Thursday, September 21st. Finally, Deutsche Bank AG upped their target price on shares of Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $42.25.

ILLEGAL ACTIVITY NOTICE: “Halyard Health, Inc. (HYH) Expected to Post Q3 2017 Earnings of $0.45 Per Share” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/23/halyard-health-inc-hyh-expected-to-post-q3-2017-earnings-of-0-45-per-share.html.

Shares of Halyard Health (HYH) opened at 44.01 on Monday. The stock’s 50 day moving average is $45.23 and its 200 day moving average is $40.71. The stock has a market cap of $2.06 billion, a PE ratio of 42.32 and a beta of 1.75. Halyard Health has a 52-week low of $31.59 and a 52-week high of $46.63.

Halyard Health (NYSE:HYH) last posted its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.14. The firm had revenue of $399.20 million for the quarter, compared to analysts’ expectations of $399.16 million. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. The business’s quarterly revenue was down .2% on a year-over-year basis. During the same quarter last year, the company posted $0.45 EPS.

A number of institutional investors have recently added to or reduced their stakes in HYH. Riverhead Capital Management LLC raised its stake in Halyard Health by 88.1% during the second quarter. Riverhead Capital Management LLC now owns 3,197 shares of the medical instruments supplier’s stock valued at $126,000 after purchasing an additional 1,497 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in Halyard Health during the first quarter valued at $153,000. LS Investment Advisors LLC raised its stake in Halyard Health by 16.1% during the second quarter. LS Investment Advisors LLC now owns 4,017 shares of the medical instruments supplier’s stock valued at $158,000 after purchasing an additional 556 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Halyard Health by 102.5% during the first quarter. Tower Research Capital LLC TRC now owns 4,836 shares of the medical instruments supplier’s stock valued at $184,000 after purchasing an additional 2,448 shares in the last quarter. Finally, QS Investors LLC raised its stake in Halyard Health by 305.6% during the second quarter. QS Investors LLC now owns 5,176 shares of the medical instruments supplier’s stock valued at $203,000 after purchasing an additional 3,900 shares in the last quarter. 91.02% of the stock is currently owned by institutional investors.

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.